ondansetron kabi 0,16 mg/ml infusionslösung
fresenius kabi deutschland gmbh (3003660) - ondansetronhydrochlorid-dihydrat - infusionslösung - 0,16 mg/ml - teil 1 - infusionslösung; ondansetronhydrochlorid-dihydrat (23418) 0,2 milligramm
lacosamid fresenius kabi 10 mg/ml infusionslösung
fresenius kabi deutschland gmbh (3003660) - infusionslösung - 10 mg/ml
cabazitaxel fresenius kabi 20 mg/ml konzentrat zur herstellung einer infusionslösung
fresenius kabi deutschland gmbh (3003660) - konzentrat zur herstellung einer infusionslösung - 20 mg/ml
tyenne
fresenius kabi deutschland gmbh - tocilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - immunsuppressiva - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.
thiotepa fresenius kabi 100 mg pulver für ein konzentrat zur herstellung einer infusionslösung
fresenius kabi deutschland gmbh (3003660) - pulver für ein konzentrat zur herstellung einer infusionslösung - 100 mg
thiotepa fresenius kabi 15 mg pulver für ein konzentrat zur herstellung einer infusionslösung
fresenius kabi deutschland gmbh (3003660) - pulver für ein konzentrat zur herstellung einer infusionslösung - 15 mg
ropivacainhydrochlorid kabi 2 mg/ml infusionslösung
fresenius kabi austria gmbh - ropivacainhydrochlorid monohydrat -
ciprofloxacin kabi 100 mg/50 ml infusionslösung
fresenius kabi austria gmbh - ciprofloxacin - fluoroquinolones
ciprofloxacin kabi 200 mg/100 ml infusionslösung
fresenius kabi austria gmbh - ciprofloxacin - fluoroquinolones
ceftriaxon kabi 1 g pulver zur herstellung einer injektions-/infusionslösung
fresenius kabi austria gmbh - ceftriaxon dinatrium - ceftriaxon